Christian Schem, MD | Authors

Expanding Role of Ovarian Suppression/ Ablation in Premenopausal ER-Positive Breast Cancer: Issues and Opportunities

January 02, 2009

Luteinizing hormone-releasing hormone analogs (LHRHa) are often used alone or in combination with tamoxifen to suppress ovarian function in premenopausal women with endocrine-responsive breast cancer. However, aromatase inhitiors (AIs) are now the preferred first-line endocrine treatment for postmenopausal women with breast cancer.